NEW YORK -- The American biotechnology company Novavax announced on Monday that its coronavirus vaccine candidate was found to have an overall efficacy of 90.4% in a Phase 3 trial conducted across the ...

Novavax, Inc. (NASDAQ:NVAX) is one of the 11 Best Short Squeeze Stocks to Buy Now. The company’s non-mRNA COVID-19 vaccine is approved, strengthening its Sanofi partnership. A closeup of a vial of the ...

The FDA recently approved new COVID-19 vaccines for Americans, but due to certain restrictions, there has been mounting confusion on what they are, how much protection they’ll offer and whether ...

DURHAM, N.C. -- Two of the COVID-19 vaccines currently in use in the United States will be effective against a variant of the virus that was first identified in California, according to researchers at ...

Shah Capital is reportedly pressing Novavax Inc. (NASDAQ:NVAX) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19 vaccine. • NVAX stock is showing ...

(Reuters) - Novavax Inc has begun a large late-stage study of its experimental COVID-19 vaccine in the United States, the drug developer said on Monday, after delaying the trial twice due to issues in ...

CHICAGO, Oct 30 (Reuters) - Novavax Inc (NVAX.O), opens new tab on Friday outlined specific diversity targets for its large-scale COVID-19 vaccine study expected to begin in the United States and ...